Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD May 22, 2017 • 4:05 PM EDT
Tonix Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Programs Update May 15, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals to Present PTSD Clinical Data at the Society of Biological Psychiatry 72nd Annual Scientific Convention May 11, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-102 SL Composition and Formulation: Designed for Transmucosal Absorption and Bedtime Daily Use May 2, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update April 17, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option April 13, 2017 • 11:30 AM EDT
Tonix Pharmaceuticals Reports Results from U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting on TNX-102 SL for Posttraumatic Stress Disorder April 11, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Completes $8 Million Public Offering of Common Stock April 4, 2017 • 11:30 AM EDT
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement April 3, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Prices Public Offering of 1,800,000 Shares of Common Stock March 30, 2017 • 8:01 AM EDT
